企業概要
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on the development of novel immunotherapies designed for the treatment of cancer. This company operates within the healthcare sector and specifically within the biotechnology industry, a domain characterized by high research and development costs and reliance on future product approvals. The firm currently employs 23 individuals and holds a market capitalization of $8.67M, while reporting annual revenue of $7.70M over the trailing twelve months. These valuation metrics indicate that the company is a small-cap entity with limited market presence, reflecting the typical scale of early-stage biotechnology firms that have not yet achieved commercial dominance. The combination of a modest market cap and single-digit revenue suggests that the enterprise is in an early phase of its lifecycle, where capital allocation is heavily dependent on external financing rather than organic cash generation.
財務健全性
The company reported revenue of $7.70M, yet incurred a net income of $-33,376,000 and an EBITDA of $-33,342,000, revealing a cost structure where expenses significantly exceed income generation. This substantial gap between positive revenue and deeply negative net income highlights the intensive operational burn rate inherent in clinical-stage biotechnology operations. The free cash flow stands at $-24,904,624, indicating that the company is consuming cash reserves to fund its operations and development pipeline without generating positive operating cash flows. The gross margin is reported at -270.8%, the operating margin at -224.2%, and the profit margin at 0.0%, all of which signal that the company is currently operating at a loss on a per-unit basis or facing significant cost inefficiencies relative to revenue recognition. On the balance sheet, the company holds $27.50M in cash against $22.96M in debt, resulting in a debt-to-equity ratio of 86.62, which suggests a leveraged financial structure typical of capital-intensive biotech firms. Despite the debt load, the current ratio is 3.59, indicating a robust short-term liquidity position where current assets substantially exceed current liabilities. The return on equity is -79.7% and the return on assets is -27.7%, metrics that demonstrate that management has not yet generated positive returns on shareholder capital or invested assets, consistent with a company still in the investment phase.
バリュエーション評価
The trailing twelve-month P/E ratio is not available (N/A) due to negative earnings, while the forward P/E is listed as -0.18, implying that the market anticipates continued negative earnings in the near term rather than an immediate earnings trajectory. The price-to-book ratio is 0.33, which indicates that the market is valuing the company at less than one-third of its book value, suggesting no market premium over the net asset value. The price-to-sales ratio is 1.13 and the EV/EBITDA is -0.12, providing alternative valuation lenses that suggest the stock is priced relative to its revenue stream rather than profitability or enterprise value multiples. The 52-week high was $9.24 and the 52-week low was $3.91, meaning the stock's price fluctuated within this range during the past year. The beta value is 0.86, indicating that the stock's price volatility is slightly lower than the broader market, suggesting somewhat lower sensitivity to general market movements compared to high-beta biotechnology peers. These valuation metrics collectively present a picture of a speculative asset priced based on potential future milestones rather than current fundamental profitability.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company is too early in its stage to report comparable growth rates against prior periods. Since the company reports zero profit margin and negative earnings, the concept of a sustainable dividend payout ratio is not applicable, and the dividend yield is N/A. Consequently, the company does not pay dividends and instead retains any minimal earnings or utilizes cash reserves to reinvest into research, development, and clinical trials. The overall growth and income profile is defined by a lack of historical growth data and an absence of income distribution, focusing entirely on capital appreciation potential derived from the success of its clinical-stage pipeline products.